PCC® probiotic and the increased interferon-γ responses in very young children with atopic dermatitis

Prescott, et al. Clinical effects of probiotics are associated with increased interferon-γ responses in very young children with atopic dermatitis. Clinical & Experimental Allergy 2005;35(12):1557-1564

This was a follow-up study to the trial that showed that administration of PCC® resulted in significant clinical improvement in very young children with moderate-to-severe atopic dermatitis.  This study examined the underlying immunological effects that were associated with the improvement in eczema symptoms.

General findings

The study found that PCC® dosing was associated with a significant increase in the Th1 immune response at both 8 and 16 weeks relative to baseline levels. No significant changes were seen in the placebo group. The degree of increase in the immune response was directly proportional to the decrease in the severity of atopic dermatitis.


The improvement in atopic dermatitis severity with PCC® treatment was associated with significant increases in the capacity for Th1 responses and altered responses to skin and gut bacteria. This effect was still evident two months after dosing with PCC® stopped.

Read the report


Supplier Member

Bioxyne Ltd.

Suite 506, Level 5
50 Clarence St
Sydney, NSW 2000, Australia

P: +61 2 9078 8180
E: info@bioxyne.com
ABN: 97 084 464 193


Sign Up